Carisma Therapeutics (NASDAQ:CARM – Get Free Report) and Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Carisma Therapeutics and Achieve Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Carisma Therapeutics | 1 | 4 | 1 | 1 | 2.29 |
| Achieve Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
Carisma Therapeutics presently has a consensus target price of $1.93, indicating a potential upside of 4,472.45%. Achieve Life Sciences has a consensus target price of $12.00, indicating a potential upside of 203.03%. Given Carisma Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Achieve Life Sciences.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Carisma Therapeutics | $10.77 million | 0.16 | -$60.48 million | $0.73 | 0.06 |
| Achieve Life Sciences | N/A | N/A | -$39.83 million | ($1.38) | -2.87 |
Achieve Life Sciences has lower revenue, but higher earnings than Carisma Therapeutics. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by insiders. Comparatively, 3.0% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Carisma Therapeutics has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.
Profitability
This table compares Carisma Therapeutics and Achieve Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Carisma Therapeutics | -254.28% | N/A | -192.17% |
| Achieve Life Sciences | N/A | -193.49% | -116.68% |
Summary
Carisma Therapeutics beats Achieve Life Sciences on 10 of the 13 factors compared between the two stocks.
About Carisma Therapeutics
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
About Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
